A series of recent reports has raised questions about the effectiveness of the 'TrumpRx' initiative, the prescription drug platform launched by the Trump administration in February 2026. The government-backed website was designed to reduce costs by aligning US drug prices more closely with those in other developed countries.
However, a March analysis by Reuters found that many medicines remain significantly cheaper under the UK system, where prescription costs are subsidised and standardised through the National Health Service. The findings suggest that while some prices have fallen, the platform has not consistently delivered the lowest available costs.
